These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37336174)

  • 1. Clinical next-generation sequencing assay combining full-length gene amplification and shotgun sequencing for the detection of CMV drug resistance mutations.
    von Bredow B; Caldera JR; Cerón S; Chan JL; Gray HK; Garner OB; Yang S
    J Clin Virol; 2023 Aug; 165():105520. PubMed ID: 37336174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance.
    Recio V; González I; Tarragó D
    Virol J; 2023 Jul; 20(1):153. PubMed ID: 37464399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing for cytomegalovirus antiviral resistance genotyping in a clinical virology laboratory.
    Chorlton SD; Ritchie G; Lawson T; McLachlan E; Romney MG; Matic N; Lowe CF
    Antiviral Res; 2021 Aug; 192():105123. PubMed ID: 34174249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.
    Sahoo MK; Lefterova MI; Yamamoto F; Waggoner JJ; Chou S; Holmes SP; Anderson MW; Pinsky BA
    J Clin Microbiol; 2013 Nov; 51(11):3700-10. PubMed ID: 23985916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.
    Garrigue I; Moulinas R; Recordon-Pinson P; Delacour ML; Essig M; Kaminski H; Rerolle JP; Merville P; Fleury H; Alain S
    J Clin Virol; 2016 Jul; 80():74-81. PubMed ID: 27214758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
    Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
    J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation.
    Jung JY; Nho D; Cho SY; Lee DG; Choi SM; Kim HJ; Kim M; Oh EJ
    J Infect Chemother; 2022 Oct; 28(10):1415-1418. PubMed ID: 35810104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutations in the
    Demin MV; Tikhomirov DS; Biderman BV; Drokov MY; Sudarikov AB; Tupoleva TA; Filatov FP
    Vopr Virusol; 2022 Mar; 67(1):37-47. PubMed ID: 35293187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.
    Chou S; Ercolani RJ; Sahoo MK; Lefterova MI; Strasfeld LM; Pinsky BA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4697-702. PubMed ID: 24890586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients.
    Kleiboeker SB
    Antiviral Res; 2023 Jul; 215():105623. PubMed ID: 37150409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
    Chou S; Satterwhite LE; Ercolani RJ
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
    Chou S; Song K; Wu J; Bo T; Crumpacker C
    J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
    Sohrabi M; Behzadian F; Hosseini SM; Lashini H
    Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to drug-resistant cytomegalovirus in transplant recipients.
    Chou S
    Curr Opin Infect Dis; 2015 Aug; 28(4):293-9. PubMed ID: 26098499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
    Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
    J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.